Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for IDEAYA Biosciences, Inc. (IDYA : NSDQ)

• Company Description    IDEAYA Biosciences Inc. is an oncology-focused precision medicine company. It focuses on the discovery and development of therapeutics for patients using molecular diagnostics. The company's product pipeline consists of IDE196, MAT2A, PARG, Pol-theta and WRN which are in clinical stage. IDEAYA Biosciences Inc. is based in South San Francisco, United States. Number of Employees: 81

• Price / Volume Information    Yesterday's Closing Price: $10.43 Daily Weekly Monthly 20 Day Moving Average: 323,273 shares Shares Outstanding: 38.64 (millions) Market Capitalization: $403.01 (millions) Beta: 1.78 52 Week High: $28.00 52 Week Low: $8.14 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.29% 9.26% 12 Week -23.42% -16.91% Year To Date -55.88% -47.53%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7000 SHORELINE COURT SUITE 350 - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-443-6209 fax: - investor@ideayabio.com http://www.ideayabio.com

• General Corporate Information    Officers Yujiro Hata - Chief Executive Officer and President Timothy Shannon - Chairman of the Board of Directors Paul Stone - Senior Vice President and Chief Financial Officer Garret Hampton - Director Susan L. Kelley - Director Peer Information IDEAYA Biosciences, Inc. (CORR.) IDEAYA Biosciences, Inc. (RSPI) IDEAYA Biosciences, Inc. (CGXP) IDEAYA Biosciences, Inc. (BGEN) IDEAYA Biosciences, Inc. (GTBP) IDEAYA Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45166A102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/09/22 Share - Related Items Shares Outstanding: 38.64 Most Recent Split Date: (:1) Beta: 1.78 Market Capitalization: $403.01 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.51 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.58 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/09/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.40 Price/Cash Flow: - Price / Sales: 12.57 EPS Growth vs. Year Ago Period: -28.57% vs. Previous Quarter: 23.40% Sales Growth vs. Year Ago Period: 56.74% vs. Previous Quarter: 283.36% ROE 03/31/22 - -19.08 12/31/21 - -18.22 09/30/21 - -14.83 ROA 03/31/22 - -14.92 12/31/21 - -13.87 09/30/21 - -10.85 Current Ratio 03/31/22 - 4.50 12/31/21 - 5.56 09/30/21 - 6.96 Quick Ratio 03/31/22 - 4.50 12/31/21 - 5.56 09/30/21 - 6.96 Operating Margin 03/31/22 - -170.82 12/31/21 - -178.09 09/30/21 - -103.19 Net Margin 03/31/22 - -170.82 12/31/21 - -178.09 09/30/21 - -103.19 Pre-Tax Margin 03/31/22 - -170.82 12/31/21 - -178.10 09/30/21 - -103.19 Book Value 03/31/22 - 7.47 12/31/21 - 7.83 09/30/21 - 8.27 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©